MSIS标准在经股骨骨整合术后感染疑似患者中的验证
本研究回顾性分析55例经股骨骨整合患者,比较感染组与非感染组的2018 MSIS血清参数,发现CRP、ESR、WBC无差异,仅PMN百分比有差异,MSIS总分无法区分感染。作者开发的新评分(各指标高于ROC阈值计1分,总分0-4)AUC为0.84,最佳 cutoff≥2时敏感性0.88、特异性0.62。
要点
- 2018 MSIS血清参数在骨整合术后患者中无法验证,MSIS总分与感染无关联。
- 新评分(CRP、ESR、WBC、PMN各计1分)AUC=0.84,cutoff≥2敏感性0.88、特异性0.62。
- 临床应重视直接临床检查、软组织改变及患者报告症状,不能仅依赖实验室参数。
核心结论
- 2018 MSIS血清参数在经股骨骨整合术后患者中无法区分感染与非感染。
- 新开发的复合评分显示出良好的判别能力(AUC=0.84),但特异性有限(0.62)。
研究设计与样本
- 二次回顾性分析,数据来自FDA IDE研究(Transfemoral Amputation Osseointegration Study)及后续纵向研究。
- 共纳入55例经股骨骨整合成年患者,感染组18例(33%),非感染组37例(67%)。
- 93%(51/55)为男性,平均年龄39±11岁,多数为战伤截肢。
- 收集感染诊断30天内的2018 MSIS血清参数(CRP、ESR、WBC、PMN百分比),排除关节液数据。
- 使用t检验比较组间参数,logistic回归评估MSIS总分与感染关联,并以CDC感染定义为金标准评估新标准。
主要发现
- CRP在感染组与非感染组分别为6.1±8.4 mg/L与2.7±4.0 mg/L(p=0.14)。
- ESR在感染组与非感染组分别为33.8±27.8 mm/hour与20.0±24.2 mm/hour(p=0.11)。
- WBC在感染组与非感染组分别为9.3±3.9 ×10^3 cells/µL与4.4±2.4 ×10^3 cells/µL(p=0.08)。
- PMN百分比在感染组显著高于非感染组(66.9%±12.2% vs 58.7%±10.7%,p=0.02)。
- MSIS总分与感染存在无关联,模型与零模型无差异(似然比χ²=1.6;p=0.21)。
关键数值与推荐
- 新评分:CRP、ESR、WBC、PMN各高于其ROC推导阈值计1分,总分0-4分。
- 新评分AUC=0.84,最佳cutoff≥2分,敏感性0.88,特异性0.62。
- 感染定义采用CDC标准:浅表感染限于皮肤,深部感染位于切口下肌肉及周围组织。
临床怎么用
- 对于经股骨骨整合术后疑似感染的患者,不应单独依赖2018 MSIS血清参数进行诊断。
- 应强调直接临床检查、软组织改变特征及患者报告症状的综合评估。
- 新评分(cutoff≥2)可作为辅助工具,但需注意其特异性较低。
局限性
- 本研究为二次回顾性分析,样本量较小(55例)。
- 研究人群以男性、创伤性截肢为主,结论外推需谨慎。
- 新评分仅在原数据集内测试,需外部验证。
- 证据等级为Level IV(诊断性研究)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major complications that may result in the removal of osseointegrated implants in patients with limb loss include peri-implant fracture, severe bone resorption, and infection. It remains challenging to diagnose and manage peri-implant infection in patients who have undergone osseointegration surgery. The Musculoskeletal Infection Society (MSIS) developed criteria to identify periprosthetic joint infection (PJI) after total joint arthroplasty during the 2018 MSIS/International Consensus Meeting; however, there is no such validated system for patients who have received osseointegrated implants, and some of the measures on the MSIS/International Consensus Meeting criteria are not applicable to osseointegrated implants. Nevertheless, establishing an adapted version of the MSIS criteria, or a comparable standardized system, would be valuable for enabling consistent diagnosis of osseointegration-associated peri-implant infections. QUESTIONS/PURPOSES: (1) Is there a difference in the serum parameters of the 2018 MSIS criteria between a cohort of patients without infection and a cohort with an infection? (2) Can the serum parameters of the 2018 MSIS criteria be validated in a population that has undergone osseointegration? (3) Can we develop a new, valid set of criteria to gauge the likelihood of infection from serum parameters for those who have undergone osseointegration? METHODS: We performed a secondary (retrospective) analysis using data from the Transfemoral Amputation Osseointegration Study, an FDA investigational device exemption study. We supplemented these data with additional participants from a separate, subsequent longitudinal study who had undergone transfemoral amputations. Both studies were conducted to determine the efficacy of an osseointegrated device in the context of patient-reported outcome measures and adverse events like infections and implant removals. The participants were drawn from both studies, which were performed at Walter Reed National Military Medical Center. Eligible patients were adults who underwent transfemoral osseointegration and who had available preoperative and/or postoperative laboratory data relevant to infection assessment. We excluded individuals with incomplete clinical records that precluded the determination of infection status. We collected serum parameters corresponding to the 2018 MSIS criteria from patients from both studies within 30 days of infection diagnosis, excluding joint aspirate data, as no joints are involved in transfemoral osseointegration. We compared the serum parameters (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], white blood cell count [WBC], and percentage of polymorphonuclear [PMN] cells) from the 2018 MSIS criteria in the 33% (18 of 55) of patients with infections to the 67% (37 of 55) of patients with no infections. A total of 93% (51 of 55) of patients were male, and the study population had a mean ± SD age of 39 ± 11 years. Most participants sustained traumatic amputations due to combat, whereas the remainder resulted from oncologic or infectious etiologies. All variables were assessed before undergoing any osseointegration surgery as part of routine care (preoperative baseline laboratory values) and during the occurrence of any suspected infection, and the study did not depend on longitudinal trajectories or repeated measures. We used the CDC definition of infection, which classified a superficial infection as an infection limited to the skin and a deep infection as an infection beneath the incision in the muscle and surrounding tissues. We used t-tests to compare serum parameters from the 2018 MSIS variables between the no infection cohort and the cohort that had an episode of an infection. To determine whether the original serum parameters from the 2018 MSIS criteria could be applied to a population undergoing osseointegration surgery, we performed a logistic regression using a generalized linear model with a binomial link. The dependent variable was the presence of any infection (superficial or deep) and the predictor was the serum parameters from the 2018 MSIS total score. Finally, we developed a novel list of criteria and tested them against this dataset to evaluate the sensitivity, specificity, and area under the receiver operating characteristic curve using the CDC definition of infection as the gold standard for the presence or absence of infection. Patient outcomes were followed for a minimum of 2 years after osseointegration surgery (Stage II). RESULTS: We found no difference between the no infection cohort and infection cohort values for the CRP (2.7 ± 4.0 mg/L versus 6.1 ± 8.4 mg/L; p = 0.14). Likewise, the ESR did not differ between the no infection and infection cohorts (20.0 ± 24.2 mm/hour versus 33.8 ± 27.8 mm/hour; p = 0.11). The WBC also did not differ between the no infection and infection cohorts (4.4 ± 2.4 ×10 3 cells/µL versus 9.3 ± 3.9 ×10 3 cells/µL; p = 0.08). However, the serum percentage of PMN was higher in the group with infections compared to the group with no infections (66.9% ± 12.2% versus 58.7% ± 10.7%; p = 0.02). We were unable to validate the serum parameters from the 2018 MSIS criteria in this osseointegration surgery population. Our generalized linear model showed that the MSIS total score was not associated with the presence of infection. Furthermore, the overall model was not different from the null model (likelihood ratio χ 2 = 1.6; p = 0.21), suggesting that the serum parameters from the 2018 MSIS criteria did not discriminate between the participants without an infection and those who developed an infection. Finally, we developed a novel list of criteria to assess the presence or absence of infection in patients who had transfemoral osseointegration by assigning 1 point for each laboratory marker (CRP, ESR, WBC, and PMN) above its respective receiver operating characteristic (ROC)-derived threshold (range 0 to 4). The composite score showed excellent discrimination of infections (area under the curve [AUC] = 0.84). The optimal cutoff was ≥ 2, which produced a sensitivity of 0.88 and a specificity of 0.62. CONCLUSION: The serum parameters of the 2018 MSIS/International Consensus Meeting definition of infection did not differ between patients with and without infection after transfemoral osseointegration surgery, but a new approach that we developed appeared sensitive but not specific for this problem in a secondary analysis of patients from prior research trials. Based on these findings, surgeons should emphasize direct clinical examination, the characteristics of soft tissue changes, and patient-reported symptoms as there is no satisfactory approach using laboratory parameters alone. LEVEL OF EVIDENCE: Level IV, diagnostic study.
引用
- Bozzay AB, Rivera JA, Rabin SE, et al. Can We Validate the Musculoskeletal Infection Society Criteria in Patients Suspected of Infection After Transfemoral Osseointegration Surgery? Clin Orthop Relat Res. 2026. PMID: 42297404. doi:10.1097/CORR.0000000000003995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。